LCN2 and neoplasm: These authors also discovered that sorafenib, an antineoplastic drug, was more potent when administered in combination with anti-Lcn-2 neutralizing antibodies, which lead to an increase in lipid peroxidation and ferroptosis in tumor tissue [139].